Pacira BioSciences, Inc. (PCRX) News

Pacira BioSciences, Inc. (PCRX): $29.26

0.79 (-2.63%)

POWR Rating

Component Grades

Momentum

C

Stability

C

Sentiment

Quality

B

Add PCRX to Watchlist
Sign Up

Filter PCRX News Items

PCRX News Results

Date Symbol Company Title Start End Change POWR Rating
Loading, please wait...

PCRX News Highlights

  • PCRX's 30 day story count now stands at 2.
  • Over the past 15 days, the trend for PCRX's stories per day has been choppy and unclear. It has oscillated between 1 and 1.
  • The most mentioned tickers in articles about PCRX are DAVE and DEC.

Latest PCRX News From Around the Web

Below are the latest news stories about PACIRA BIOSCIENCES INC that investors may wish to consider to help them evaluate PCRX as an investment opportunity.

Pacira Appoints Frank D. Lee as Chief Executive Officer

-- Transformational Leader Brings Three Decades of Global Experience in Pharmaceutical and Biotechnology Product Development and Commercialization -- -- Paul J. Hastings Named Chair of the Board -- -- Dave Stack to Remain in Advisory Role through August 2025 -- TAMPA, Fla., Dec. 21, 2023 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc. (Nasdaq: PCRX), the industry leader in its commitment to non-opioid pain management and regenerative health solutions, today announced that its Board of Directors (th

Yahoo | December 21, 2023

Hedge Funds are Betting on These 14 Sliding Stocks

In this article, we will take a look at the hedge funds that are betting on these 14 sliding stocks. To see more such companies, go directly to Hedge Funds are Betting on These 5 Sliding Stocks. Stocks jumped on December 6 after the release of yet another welcome data point for the Federal Reserve, […]

Yahoo | December 6, 2023

Pacira (PCRX) Gets FDA Nod for Exparel's Label Expansion

The FDA approves Pacira's (PCRX) supplemental new drug application to expand the label of Exparel to include both sciatic and femoral nerve blocks.

Yahoo | November 13, 2023

Pacira Announces FDA Approval of Expanded EXPAREL Label to Include Two Additional Nerve Block Indications

— EXPAREL is the only FDA-approved single-dose regional analgesic to safely demonstrate four days of superiority versus bupivacaine in two clinical studies — — New indications for use as an adductor canal block and sciatic nerve block in the popliteal fossa will significantly extend reach within more than 3 million lower extremity procedures — TAMPA, Fla., Nov. 10, 2023 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc. (NASDAQ: PCRX), the industry leader in its commitment to non-opioid pain managemen

Yahoo | November 10, 2023

Pacira BioSciences to Participate in Fireside Chat at Two Healthcare Conferences in November

TAMPA, Fla., Nov. 07, 2023 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc. (NASDAQ: PCRX) today announced that it will participate in an analyst-led fireside chat at the following two healthcare conferences: Jefferies London Healthcare Conference on Tuesday, November 14th at 11:00AM GMT (6:00AM ET).35th Annual Piper Sandler Healthcare Conference on Tuesday, November 28th at 2:00PM ET. Live audio of the events can be accessed by visiting the “Events” page of the company’s website at investor.pacira.

Yahoo | November 7, 2023

Pacira BioSciences, Inc. (NASDAQ:PCRX) Q3 2023 Earnings Call Transcript

Pacira BioSciences, Inc. (NASDAQ:PCRX) Q3 2023 Earnings Call Transcript November 2, 2023 Pacira BioSciences, Inc. misses on earnings expectations. Reported EPS is $0.72 EPS, expectations were $0.84. Operator: Good day, and thank you for standing by. Welcome to the Q3 2023 Pacira BioSciences Earnings Conference Call. At this time, all participants are in a listen-only […]

Yahoo | November 4, 2023

Are Pacira BioSciences, Inc.'s (NASDAQ:PCRX) Fundamentals Good Enough to Warrant Buying Given The Stock's Recent Weakness?

It is hard to get excited after looking at Pacira BioSciences' (NASDAQ:PCRX) recent performance, when its stock has...

Yahoo | November 3, 2023

Pacira (PCRX) Q3 Earnings and Revenues Miss, '23 View Updated

Pacira (PCRX) announces weaker-than-expected third-quarter 2023 results. The company streamlines its 2023 guidance for net Exparel sales.

Yahoo | November 2, 2023

Pacira BioSciences Inc (PCRX) Reports Q3 2023 Financial Results

Net Income of $10.9 Million Despite Slight Decrease in Total Revenues

Yahoo | November 2, 2023

Pacira BioSciences Reports Third Quarter 2023 Financial Results

-- New ASA initiatives to advance education and innovation for the anesthesia community -- -- PDUFA action date for EXPAREL as a lower extremity nerve block on track for November 13, 2023 -- -- Conference call today at 8:30 a.m. ET -- TAMPA, Fla., Nov. 02, 2023 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc. (Nasdaq: PCRX), the industry leader in its commitment to non-opioid pain management and regenerative health solutions, today reported financial results for the third quarter of 2023. Third Quar

Yahoo | November 2, 2023


Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!